Undisclosed antibodies / Evotec, Zymedi, Yonsei University - LARVOL DELTA

Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases (Evotec Press Release) - "Evotec SE...announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic therapies to treat lung diseases, including asthma and idiopathic pulmonary fibrosis (IPF). The project will focus on the preclinical development of novel anti-inflammatory and anti-fibrotic antibodies directed against tRNA synthetases, an emerging therapeutic target class to treat diseases with a high unmet medical need."

Financing • Asthma • Idiopathic Pulmonary Fibrosis